-0.000261739696516092 5.36901941572684E-05 0.000691261249773476 0.000718106346852187 -0.000221472050898255 0.00156037126769263 -0.000100669114044592 0.000778507815278942
Sign Up Today X
Thanks for submitting the form.
Stockreport

JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death [Yahoo! Finance]

Regeneron Pharmaceuticals, Inc. (REGN)  More Company Research Source: Yahoo! Finance
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
In November 2025, Intellia announced that in the MAGNITUDE trial (NCT06128629) of nexiguran ziclumeran, an in vivo CRISPR therapy, for transthyretin (ATTR) amyloidosis, a male patient in his 80s died after receiving the study drug. The therapy is being developed in partnership with Regeneron. Speaking at the JP Morgan Healthcare Conference 2026, Intellia CEO John Leonard said that the patient attended the emergency room due to abdominal pain, where tests revealed elevated transaminase. During his stay in the hospital, it was revealed that the patient had air in his abdomen and received surgery where a perforation and ulcer were found. The patient died following a case of sepsis. The update on the circumstances of the patient's death may provide investors with more confidence in the safety of the gene therapy, especially given liver-associated patient deaths in gene therapy studies by other companies, including Sarepta and Pfizer Leonard said that the company has three ongoing [Read more]
IMPACT SNAPSHOT EVENT TIME: REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
REGN alerts
from News Quantified
REGN
NEWS
REGN
Earnings
REGN
Analyst Actions
REGN
SEC Filings
Stockreport

JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death [Yahoo! Finance]

Regeneron Pharmaceuticals, Inc.  (REGN) 
More Company Research Source: Yahoo! Finance
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
In November 2025, Intellia announced that in the MAGNITUDE trial (NCT06128629) of nexiguran ziclumeran, an in vivo CRISPR therapy, for transthyretin (ATTR) amyloidosis, a male patient in his 80s died after receiving the study drug. The therapy is being developed in partnership with Regeneron. Speaking at the JP Morgan Healthcare Conference 2026, Intellia CEO John Leonard said that the patient attended the emergency room due to abdominal pain, where tests revealed elevated transaminase. During his stay in the hospital, it was revealed that the patient had air in his abdomen and received surgery where a perforation and ulcer were found. The patient died following a case of sepsis. The update on the circumstances of the patient's death may provide investors with more confidence in the safety of the gene therapy, especially given liver-associated patient deaths in gene therapy studies by other companies, including Sarepta and Pfizer Leonard said that the company has three ongoing [Read more]
IMPACT SNAPSHOT
EVENT TIME:
REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS